Healthcare provider profile · identity verified

Luis A Almonte, MD

Internal Medicine · OZONE PARK, NY · NPI 1386759231

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	875	242
Atorvastatin Calcium	Atorvastatin Calcium	798	235
Rosuvastatin Calcium	Rosuvastatin Calcium	723	239
Metformin Hcl	Metformin Hcl	539	148
Losartan Potassium	Losartan Potassium	433	121
Jardiance	Empagliflozin	367	77
Hydrochlorothiazide	Hydrochlorothiazide	343	89
Valsartan	Valsartan	293	70
Fluticasone Propionate	Fluticasone Propionate	209	83
Levothyroxine Sodium	Levothyroxine Sodium	203	43
Chlorthalidone	Chlorthalidone	194	49
Novolog Flexpen	Insulin Aspart	187	42
Metoprolol Succinate	Metoprolol Succinate	177	54
Pantoprazole Sodium	Pantoprazole Sodium	159	78
Trulicity	Dulaglutide	134	27
Carvedilol	Carvedilol	123	27
Ozempic	Semaglutide	120	20
Tradjenta	Linagliptin	120	29
Januvia	Sitagliptin Phosphate	119	23
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	114	28
Ezetimibe	Ezetimibe	112	36
Potassium Chloride	Potassium Chloride	112	31
Lisinopril	Lisinopril	108	30
Vascepa	Icosapent Ethyl	106	30
Glipizide	Glipizide	105	31
Tresiba Flextouch U-100	Insulin Degludec	105	22
Escitalopram Oxalate	Escitalopram Oxalate	101	26
Alcohol Prep Pads	Alcohol Antiseptic Pads	100	38
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	99	25
Ibandronate Sodium	Ibandronate Sodium	93	32
Vitamin D2	Ergocalciferol (Vitamin D2)	92	32
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	87	24
Tamsulosin Hcl	Tamsulosin Hcl	87	29
Gabapentin	Gabapentin	85	41
Irbesartan	Irbesartan	85	22
Duloxetine Hcl	Duloxetine Hcl	83	43
Diclofenac Sodium	Diclofenac Sodium	79	27
Furosemide	Furosemide	75	19
Farxiga	Dapagliflozin Propanediol	74	17
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	74	19
Trazodone Hcl	Trazodone Hcl	72	20
Atenolol	Atenolol	66	17
Montelukast Sodium	Montelukast Sodium	62	12
Famotidine	Famotidine	57	22
Simvastatin	Simvastatin	55	20
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	54	15
Candesartan Cilexetil	Candesartan Cilexetil	53	14
Alendronate Sodium	Alendronate Sodium	52	15
Meclizine Hcl	Meclizine Hcl	52	33
Janumet	Sitagliptin Phos/Metformin Hcl	51	11
Glipizide Er	Glipizide	48	13
Single Use Swab	Alcohol Antiseptic Pads	46	25
Fenofibrate	Fenofibrate	44	13
Meloxicam	Meloxicam	43	37
Fluocinonide	Fluocinonide	40	22
Sertraline Hcl	Sertraline Hcl	40	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	36	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	35	17
Calcitriol	Calcitriol	35	suppressed
Enalapril Maleate	Enalapril Maleate	34	suppressed
Lactulose	Lactulose	34	11
Nitrofurantoin	Nitrofurantoin Macrocrystal	34	29
Olmesartan Medoxomil	Olmesartan Medoxomil	34	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	32	13
Triamcinolone Acetonide	Triamcinolone Acetonide	32	21
Ketoconazole	Ketoconazole	31	16
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Levofloxacin	Levofloxacin	28	23
Folic Acid	Folic Acid	26	suppressed
Prednisone	Prednisone	26	21
Omeprazole	Omeprazole	25	12
Allopurinol	Allopurinol	24	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	24	suppressed
Admelog Solostar	Insulin Lispro	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Metronidazole	Metronidazole	22	19
Nifedipine Er	Nifedipine	22	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	21	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	21	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	21	19
Hydrocortisone	Hydrocortisone	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	18
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Glimepiride	Glimepiride	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Naproxen	Naproxen	18	16
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	13
Labetalol Hcl	Labetalol Hcl	17	suppressed
Tresiba Flextouch U-200	Insulin Degludec	17	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	15	suppressed
Azithromycin	Azithromycin	15	15
Comfort Ez Pen Needle	Pen Needle, Diabetic	15	suppressed
Ammonium Lactate	Ammonium Lactate	14	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	14
Creon	Lipase/Protease/Amylase	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	14
Insulin Lispro Kwikpen U-100	Insulin Lispro	14	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	13	suppressed
Easy Comfort Pen Needle	Pen Needle, Diabetic	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Finasteride	Finasteride	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error